- Healthcare 150
- Posts
- Healthcare's Next $190B Opportunity
Healthcare's Next $190B Opportunity
GLP-1s are evolving into a multi-disease platform, AI is reshaping pharma operations, and healthcare is regaining investor momentum.
This week's issue examines how GLP-1 therapies are reshaping healthcare—from the next phase of obesity care and market expansion to the ripple effects across MedTech, digital health, and healthcare services.
As adoption accelerates, the biggest opportunities may extend beyond drug manufacturers, creating new winners across the broader healthcare ecosystem.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
DATA DIVE
Obesity Is Driving the Next Phase of GLP-1 Growth
While GLP-1 therapies were originally developed for type 2 diabetes, future growth will be driven overwhelmingly by obesity. According to J.P. Morgan, the number of U.S. patients using GLP-1 therapies is expected to increase from 5.1 million in 2023 to 30.3 million by 2030. Nearly two-thirds of that growth will come from obesity treatment, with obesity patients projected to rise from 0.8 million to 19.6 million, compared to diabetes patients increasing from 4.3 million to 10.7 million.
Why it matters: This shift fundamentally expands the addressable market. Rather than serving a niche diabetes population, GLP-1 therapies are becoming a mainstream chronic disease platform, opening new opportunities for pharmaceutical companies, payers, providers, and the broader healthcare ecosystem.
(More)
HEALTHTECH CORNER
AI's Biggest Opportunity in Life Sciences Isn't Drug Discovery
When people think about AI in pharma, they usually picture drug discovery. But KPMG's latest Global Tech Report suggests the biggest value creation may come elsewhere.
Executives expect AI to generate the strongest impact in data science & biostatistics (57%), while pricing & market access is projected to become one of the fastest-growing use cases over the next five years (46% today vs. 51% in five years). Clinical development, medical affairs and commercial operations also remain high-priority investment areas.
Why it matters: The next generation of AI winners may not be the companies discovering new molecules, but those optimizing how therapies are developed, priced, reimbursed and brought to market. For investors, that shifts attention toward infrastructure, analytics and workflow software rather than pure discovery platforms.
COMPETITIVE LANDSCAPE SNAPSHOT
TREND TO WATCH
Healthcare's Comeback Is Becoming an Investment Thesis
After several years of lagging broader markets, healthcare is beginning to regain investors' attention. The drivers are changing. Pricing uncertainty is gradually easing, M&A activity is accelerating as large pharmaceutical companies prepare for the upcoming patent cliff, and innovation across biotech and MedTech remains resilient despite a more disciplined funding environment.
Rather than chasing speculative growth, investors are increasingly focusing on companies with durable pipelines, strong cash generation and differentiated technologies that can deliver measurable clinical and commercial outcomes. The sector is also benefiting from a more constructive capital allocation environment, with strategic acquisitions once again becoming a key growth lever.
Why it matters: Healthcare is shifting from a defensive allocation to a strategic growth opportunity. As capital returns to the sector, companies combining innovation with execution—not just breakthrough science—are likely to command the strongest investor interest.
INTERESTING ARTICLES
